China News Service, March 2. According to the website of the State Drug Administration on the 2nd, on March 1, the State Drug Administration approved the recombinant novel coronavirus protein vaccine (CHO) of Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd. with conditions. cells) marketing registration application.
The vaccine is the first approved domestic recombinant new coronavirus protein vaccine, which is suitable for the prevention of disease caused by new coronavirus infection (COVID-19).
According to the relevant provisions of the "Vaccine Administration Law" and "Drug Administration Law", the State Food and Drug Administration will conduct emergency review and approval in accordance with the special drug approval procedures, and approve the application for marketing registration of the vaccine with conditions.
The State Food and Drug Administration requires the marketing license holder of the vaccine to continue to carry out relevant research work, complete the conditional requirements, and submit the follow-up research results in a timely manner.
Screenshot of the website of the State Drug Administration